Researchers at Cleveland Clinic are participating in a new clinical trial
designed to test the effectiveness of using a currently-approved diabetes drug to prevent the development of Alzheimer’s Disease in people who are predisposed to develop the condition.
The study will also look at whether a new genetic biomarker, TOMM40, is an additional indication of a patient’s elevated risk of developing the disease.
The TOMMORROW trial, a Phase 3, five-year, double-blind, placebo-controlled study, is the nation’s largest prevention clinical trial for Alzheimer’s disease. The trial examines if the drug pioglitazone (AD-4833), currently FDA approved to treat type 2 diabetes, reduces inflammation and has a protective effect in the brain that can prevent high risk-patients from developing mild cognitive disorder and Alzheimer’s disease.
The link between type 2 diabetes and Alzheimer's may occur as a result of the complex ways that type 2 diabetes affects the ability of the brain and other body tissues to use sugar (glucose) and respond to insulin.For more information on this trial and Cleveland Clinic Lou Ruvo Center for Brain Health, call 855-LOU-RUVO (1-855-568-7886), visit www.clevelandclinic.org/brainhealth or email email@example.com.